Premium
Zila (MM) (ZILAD)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Zila, Inc. (NASDAQ:ZILAD) today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has issued an indefinite renewal of the marketing...
Oral cancer kills one American every hour, largely due to late detection. It used to be known as a disease of older men with histories of heavy smoking or drinking. But...
Zila, Inc. (NASDAQ:ZILAD) today announced encouraging preliminary results of an in vivo animal study which showed evidence of photodestruction of premalignant lesions and...
Zila, Inc. (NASDAQ:ZILAD) today announced that Wade F. Brooksby has been elected to the company?s Board of Directors and will serve on the audit committee. The appointment...
Zila, Inc. (Nasdaq:ZILAD) today announced that, as a result of suspicious end-of-day trading in the Company?s stock during the past several weeks, the Company has made an urgent...
Zila, Inc. (Nasdaq:ZILAD) today reported financial results for its fiscal 2008 fourth quarter and full year ended July 31, 2008. During the third and fourth quarters of fiscal...
Zila, Inc. (NASDAQ:ZILAD) today announced that it has retained investment bank William Blair & Company to assist it in exploring strategic business opportunities. ?In...
Zila, Inc. (NASDAQ:ZILAD) today announced that ViziLite? Plus with TBlue?, its flagship oral cancer screening product, will be prominently featured at the British Dental Trade...
Zila, Inc. (Nasdaq:ZILAD) today announced that it will release its financial results for the fiscal 2008 fourth quarter and full year ended July 31, 2008, after the market...
Zila, Inc. (NASDAQ:ZILAD) today announced that it received a Nasdaq Staff Determination Letter on September 22, 2008 informing the company that it is subject to delisting based...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
